Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Clinical utility of ursodeoxycholic acid in preventing flutamide-induced hepatopathy in patients with prostate cancer: a preliminary study.

Kojima M, Kamoi K, Ukimura O, Fujito A, Nakao M, Tanaka S, Miyashita H, Iwamoto N, Ohe H, Kitamori T, Date S, Kitamura K, Araki H, Aoki T, Imada N, Takada H, Imaide Y, Mikami K, Uchida M, Saitoh M, Miki T.

Int J Urol. 2002 Jan;9(1):42-6. Erratum in: Int J Urol. 2002 Aug;9(8):473..

2.

Flutamide-induced toxic hepatitis. Potential utility of ursodeoxycholic acid administration in toxic hepatitis.

Cicognani C, Malavolti M, Morselli-Labate AM, Sama C, Barbara L.

Dig Dis Sci. 1996 Nov;41(11):2219-21.

PMID:
8943975
3.

[Changes in liver function induced by flutamide in patients with prostate cancer (studies in patients treated with total androgen blockage)].

Ikemoto I, Ohishi Y, Yamazaki H, Wada T, Aizawa Y.

Nihon Hinyokika Gakkai Zasshi. 2000 Jun;91(6):556-61. Japanese.

4.

[Therapeutic options for drug induced liver injury: the efficacy of UDCA based on EBM].

Matsuzaki Y, Nishikawa K.

Nihon Shokakibyo Gakkai Zasshi. 2003 Jun;100(6):659-66. Review. Japanese. No abstract available.

PMID:
12833859
5.

Antiandrogen-associated hepatotoxicity in the management of advanced prostate cancer.

Lin AD, Chen KK, Lin AT, Chang YH, Wu HH, Kuo JY, Huang WJ, Hsu YS, Chung HJ, Chang LS.

J Chin Med Assoc. 2003 Dec;66(12):735-40.

PMID:
15015823
6.

Flutamide-induced acute hepatitis in advanced prostate cancer patients.

Kraus I, Vitezic D, Oguic R.

Int J Clin Pharmacol Ther. 2001 Sep;39(9):395-9.

PMID:
11563686
7.

[Clinical efficacy of treatment with low-dose flutamide in maximum androgen blockade therapy].

Shimizu K, Kiyohara H, Nakayama J, Fujii T, Hosomi M.

Hinyokika Kiyo. 2001 Apr;47(4):251-5. Japanese.

8.

[Hepatic encephalopathy induced by flutamide administered for the treatment of prostatic cancer].

Patel H, Rhee E, Zimmern PE.

J Urol (Paris). 1996;102(3):123-5. Review. French.

PMID:
9091557
9.

Recommended dose of flutamide with LH-RH agonist therapy in patients with advanced prostate cancer.

Akaza H, Isaka S, Usami M, Kanetake H, Kotake T, Koiso K, Aso Y.

Int J Urol. 1996 Nov;3(6):468-71.

10.

Incidence of liver toxicity associated with the use of flutamide in prostate cancer patients.

Gomez JL, Dupont A, Cusan L, Tremblay M, Suburu R, Lemay M, Labrie F.

Am J Med. 1992 May;92(5):465-70.

PMID:
1349790
11.

[Hepatotoxicity due to flutamide].

Ruiz R, Casañ R, Juan O.

Aten Primaria. 2001 Nov 15;28(8):565. Spanish. No abstract available.

12.

[Fulminant hepatitis caused by flutamide].

Andréjak M, Nguyen-Khac E, Decocq G, Capron JP.

Gastroenterol Clin Biol. 1996 Feb;20(1):121-2. French. No abstract available.

PMID:
8734324
13.

[Hepatotoxicity of flutamide].

Wietzke P, Münke H, Hartmann H, Ramadori G.

Z Gastroenterol. 1997 Aug;35(8):631-5. German. No abstract available.

PMID:
9381745
14.

Suspected cross-hepatotoxicity of flutamide and cyproterone acetate.

Miquel M, Soler A, Vaqué A, Ojanguren I, Costa J, Planas R.

Liver Int. 2007 Oct;27(8):1144-7.

PMID:
17845544
15.

[Fulminant hepatitis associated with treatment with flutamide].

García-Gascó P, Morata Aldea C, Segura Huertas A, Aparicio Urtasun J.

Med Clin (Barc). 1997 Dec 6;109(20):820. Spanish. No abstract available.

PMID:
9493166
16.
17.

Microscopic polyangiitis complicated by the development of prostate cancer and flutamide-induced hepatitis.

Papaioannides D, Korantzopoulos P, Bouropoulos C, Latsi P, Fotinou M, Orphanidou D.

Int Urol Nephrol. 2005;37(3):515-20.

PMID:
16307333
18.

Flutamide-induced hepatotoxicity: report of a case series.

García Cortés M, Andrade RJ, Lucena MI, Sánchez Martínez H, Fernández MC, Ferrer T, Martín-Vivaldi R, Peláez G, Suárez F, Romero-Gómez M, Montero JL, Fraga E, Camargo R, Alcántara R, Pizarro MA, García-Ruiz E, Rosemary-Gómez M.

Rev Esp Enferm Dig. 2001 Jul;93(7):423-32. English, Spanish. Erratum in: Rev Esp Enferm Dig 2001 Oct;93(10):634.

PMID:
11685939
19.

Prolonged prostate-specific antigen response in flutamide withdrawal syndrome despite disease progression.

Longmore L, Foley JP, Rozanski TA, Higgins B, Thompson IM.

South Med J. 1998 Jun;91(6):573-5.

PMID:
9634122

Supplemental Content

Support Center